Adoptive Cell Therapeutics: Logistics & Lab Testing - with English Subtitles

Adoptive cell therapies such as chimeric antigen receptor T-cells (CAR T cells) have transformed cancer therapies and hold great promise for a widening range of oncology indications. However, orchestration of these products and lab testing in clinical trials is complex and presents unique challenges to ensuring product safety and efficacy. This includes maintaining product integrity, chain of identity, chain of custody, as well as demonstration of control of the product's critical quality attributes, all on a per-patient basis. Moreover, biomarker analyses play a critical role in patient identification, pharmacokinetic (PK) assessments of the treatment dose, characterization of pharmacodynamics (PD) and target engagement response. All of these factors need to be addressed during clinical trials of these products, and often require creative solutions to meet the diverse needs of sponsors, patients and investigator sites. Download this webinar to learn more about running clinical trials for adoptive cell therapies.

Copy and paste this URL:

https://biopharma.labcorp.com/latest-thinking/explore-library/detail.html/covance/assetLibrary/videos/Adoptive-Cell-Therapeutics-Logistics-Lab-Testing.png